KN
KNTPF.US Kintor Pharmaceutical Limited
- Market cap
- USD 76.6M
- P/E
- -
- P/B
- 4.68x
- ROE
- -273.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is KNTPF.US undervalued?
Graham numberThe Graham number of Kintor Pharmaceutical Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kintor Pharmaceutical Limited fundamental analysis
No fundamental analysis for Kintor Pharmaceutical Limited yet.
Kintor Pharmaceutical Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing AL…
Full company profileKintor Pharmaceutical Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kintor Pharmaceutical Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.46M | 490K | 698.00 | 0.00 | 0.00 | 34.2M | 0.00 | 0.00 | 5.00M | 31.8M | 205M |
| Gross Profit | 1.09M | 140K | 9.00 | 0.00 | -942K | 34.2M | -2.74M | -42.2M | -4.73M | -24.5M | 87.5M |
| Operating Income | -58.9M | -46.1M | -110K | -218M | -505M | -840M | -945M | -152M | -145M | -197M | -322M |
| EBITDA | -58.4M | -44.4M | -102M | -214M | -393M | -824M | -951M | -1.05B | -128M | -164M | -248M |
| Net Income | -54.2M | -46.2M | -108K | -233M | -508M | -842M | -954M | -1.06B | -155M | -195M | -299M |
| EPS | -0.29 | -0.24 | 0.00 | -0.97 | -1.64 | -2.36 | -2.53 | -2.47 | -0.36 | -0.43 | -0.61 |
| Balance Sheet | |||||||||||
| Total Assets | 16.9M | 49.1M | 424K | 553K | 1.85B | 2.07B | 2.06B | 869M | 515M | 341M | 319M |
| Total Liabilities | 100K | 45.5M | 172K | 184K | 344M | 413M | 560M | 411M | 221M | 158M | 210M |
| Shareholders' Equity | 16.8M | 3.63M | 252K | 370K | 1.51M | 1.66B | 1.50B | 458M | 294M | 183M | 109M |
| Cash & Short-term Investments | 9.64M | 29.2M | 138K | 197K | 1.39M | 1.06M | 877K | 455M | 149M | 34.8M | 31.8M |
| Total Debt | - | 45.0M | 69.6M | 64.1M | 222M | 160M | 286M | 254M | 133M | 86.6M | 134M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.5K | -45.0K | -115K | -228K | -381K | -1.05M | -961K | -388M | -199M | -170M | -200M |
| Capital Expenditure | 2.66K | 11.9K | 5.25K | 67.2K | 69.0K | 76.2K | 27.5K | 2.72M | 1.68M | 742K | 200M |
| Free Cash Flow | -17.2K | -56.9K | -120K | -295K | -450K | -1.13M | -989K | -390M | -201M | -170M | - |
| Ratios | |||||||||||
| ROE | -321.8% | -1,272.9% | -43.1% | -62,915.8% | -33,708.4% | -50.9% | -63.8% | -231.6% | -52.8% | -106.7% | -273.7% |
| ROA | -319.9% | -94.1% | -25.6% | -42,028.7% | -27.5% | -40.7% | -46.4% | -122.0% | -30.1% | -57.2% | -93.7% |
| Net Profit Margin | -3,718.3% | -9,433.5% | -15,542.1% | - | - | -2,460.0% | - | - | -3,105.8% | -612.3% | -145.6% |
| Debt to Equity | - | 12.39x | 276.72x | 173.39x | 147.02x | 0.10x | 0.19x | 0.55x | 0.45x | 0.47x | 1.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kintor Pharmaceutical Limited dividends
Kintor Pharmaceutical Limited has not paid dividends in the last 9 fiscal years.
Who owns Kintor Pharmaceutical Limited
- Insiders 12.05%
- Institutions 9.86%
- Public & others 78.09%
- Shares outstanding 489M
- Free float 382M
Kintor Pharmaceutical Limited company profile
- Company name
- Kintor Pharmaceutical Limited
- Ticker
- KNTPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 122
- Fiscal year end
- December
- Address
- Suzhou Industrial Park, Suzhou, China, 215123
- Phone
- 86 51 2626 39909
- Website
- kintor.com.cn
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours that is in phase I and II clinical trial; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer that is in phase I clinical trial; and GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC) that is in phase I clinical trial. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Kintor Pharmaceutical Limited management
4- Dr. Youzhi TongFounder, CEO & Executive Chairman · born 1962
- Dr. Xiang NiChief Medical Officer & Executive Director · born 1969
- Mr. Joseph H. J. ChengChief Financial Officer · born 1978
- Mr. Wai Chiu Wong C.P.A., CTP, FCSCompany Secretary · born 1955